Surface Oncology announced Ramy Ibrahim, M.D., will join the company’s board of directors. Dr. Ibrahim is a medical oncologist currently serving as chief medical officer and vice president of clinical development at the Parker Institute for Cancer Immunotherapy. Dr. Ibrahim is an acknowledged immunotherapy expert and played an important role in the development of several of the first-generation immune checkpoint inhibitor therapies. Prior to the Parker Institute for Cancer Immunotherapy, Dr. Ibrahim was at AstraZeneca, where he served as the vice president of clinical development for immuno-oncology and led the development of the early checkpoint inhibitor antibodies durvalumab (Imfinzi®) and tremelimumab. Previously, at Bristol-Myers Squibb, he played a key role in the clinical development of ipilimumab (Yervoy®), the first FDA-approved immune checkpoint inhibitor, from early phase II through multiple global launches. He also played a key role in the early development of nivolumab (Opdivo®), as well as the development of anti-PD-L1 and anti-CD137 antibody programs. Dr. Ibrahim is actively involved in global cancer immunotherapy networks such as the Society of Immunotherapy for Cancer (SITC), Ludwig Institute, the Cancer Research Institute and the Cancer Immunotherapy Trials Network. Dr. Ibrahim trained in medicine and medical oncology at Cairo University then conducted bench and clinical immunotherapy research at the cancer vaccine branch of the National Cancer Institute in Bethesda, Maryland, prior to moving into industry.